AI-Native Scoping Reviews & Evidence Mapping

This paper shows that DCB is not just a technical upgrade over POBA, but a consistently stronger strategy for restenosis-prone vascular disease, with better patency and fewer repeat interventions across coronary ISR, femoropopliteal lesions, BTK disease, and dialysis access. The full paper is worth reading because it reveals where that advantage is most convincing, where technique and vessel preparation change the outcome, and how much of DCB’s real-world value lies in selecting the right lesion, not just the device.

This paper shows that carotid shunts are neither universally protective nor universally harmful: they can reduce stroke risk in selected high-risk carotid surgery patients, but they also introduce their own complications. It is worth reading because it maps when shunting may truly help, when it may be unnecessary, and how monitoring can guide a safer, more tailored surgical strategy.

This review shows where thrombolysis in DVT truly helps and where it does not: the clearest signal is in selected iliofemoral disease, where modern catheter-based clot removal may improve patency and reduce post-thrombotic syndrome, but only at the cost of real bleeding risk. Read the full paper to see which techniques look most promising, which patients benefit most, and where the evidence still breaks down.

This paper shows that CT angiography in carotid stenosis is not just about measuring narrowing: it can reveal plaque vulnerability, near-occlusion, carotid webs, and hidden stroke risk that standard stenosis thresholds may miss. It is worth reading because it maps where CT truly adds clinical value, where it can mislead, and how more structured CTA reporting could change decision-making.

This review shows that DVT is not just a problem of stasis — it is a biologically active inflammatory process driven by endothelial injury, platelet–leukocyte crosstalk, and NET-mediated immunothrombosis. Read the full paper to see which mechanisms are strongest, which patient phenotypes carry the clearest signals, and which emerging biomarkers and targets could reshape risk stratification and therapy.

The main message of this paper is that current treatment of atherosclerosis relies mainly on standard preventive therapies—cholesterol lowering, combination lipid therapy, and blood-pressure control—whereas future treatment may come from more precise targeting of inflammation, endothelial injury, oxidative stress, immune pathways, and plaque biology. The review maps 47 original research topics, from combination therapies to cannabinoid receptor modulation, and 10 recurrent directions in the non-original literature, from lipid reduction to personalized imaging of plaque burden.

The paper tackles one of endovascular medicine’s most controversial questions: whether DCBs truly carry a late mortality risk. Mapping 170 original studies, it shows why the feared signal largely fades in broader evidence, where comorbidity and indication matter more than the device itself — and reveals the few settings where uncertainty still remains.

This review maps a large clinical evidence base showing that COVID-19 vaccines were generally linked to a strong safety-benefit balance: serious complications such as myocarditis and VITT were rare, while protection against severe COVID-19 outcomes and death remained substantial. Read the full paper to see which risks were truly recurrent, which populations were most vulnerable, and how the balance differed by vaccine platform, age, pregnancy, chronic disease, and immunocompromised status.

This review shows that COVID-19 vaccination was generally linked to lower mortality, especially in older and high-risk groups, but that protection decreased over time and improved again after booster doses. Read the full paper to see where the evidence is strongest, which groups benefit most, and where important safety and interpretation questions remain.

This paper shows that daylight saving time is not a harmless calendar ritual: the clock changes align with measurable spikes in mortality, suicide, cardiovascular events, sleep loss, and road danger, with the spring and autumn transitions carrying distinct risks. Read the full paper to see where the strongest signals emerge, which outcomes remain inconsistent, and why the evidence increasingly points toward ending biannual clock changes rather than treating them as a neutral social habit.

This paper shows that coffee is not simply “good” or “bad” for health: moderate intake is repeatedly linked with lower risks of stroke, dementia, diabetes, and death, while higher intake and certain coffee types can also carry harm signals. Read the full paper to see where the benefits look most convincing, where the evidence becomes conflicting, and which patients may need more caution than the usual “2–3 cups a day” message suggests.

This paper shows that coffee is not a proven anti-aging therapy, yet the mapped evidence still suggests a biologically plausible link to longer survival through oxidative-stress and insulin/IGF-1 pathways, with human data pointing to modest benefit rather than clear harm. Read the full text to see where the real signal lies, which findings are only indirect or genotype-specific, and why the apparent longevity story of coffee is much more nuanced than popular health claims suggest.